Apolipoprotein B versus lipoprotein lipids: Vital lessons from the AFCAPS/TexCAPS trial

CMAJ. Canadian Medical Association Journal

Volumn 164, Issue 1, 2001, Pages 44-47

  Sniderman, A D ^a   Bergeron, J ^a   Frohlich, J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CANADA; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; NOTE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035830345     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (43)

1. A receptor-mediated pathway for cholesterol homeostasis
2. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
3. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
4. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study
5. Asymptomatic hypercholesterolemia: A clinical policy review
6. Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults
7. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease
8. The effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels
9. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material
10. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan
11. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study
12. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk
13. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study)
14. The adipocyte, fatty acid trapping, and atherogenesis
15. Comparison of arterial intimal clearances of LDL from diabetic and nondiabetic cholesterol-fed rabbits. Differences in intimal clearance explained by size differences
16. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system
17. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction
18. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study
19. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity
20. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes
21. Low density lipoprotein subfractions increase thromboxane formation in endothelial cells
22. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects
23. Dense low density lipoprotein sub-species with diminished oxidative resistance predominate in combined hyperlipidemia
24. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages
25. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans
26. Low density lipoprotein subfractions and [Ca2+]i in vascular smooth muscle cells
27. Modulation of apolipoprotein B antigenic determinants in human low-density lipoprotein subclasses
28. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size
29. Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). Association of altered proteolytic accessibility with decreased receptor binding of LDL subspecies from hypertriglyceridemic subjects
30. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men
31. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS)
32. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project
33. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
34. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
35. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
36. LDL size and risk of coronary heart disease in elderly men and women
37. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study
38. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
39. Thrombogenic factors and recurrent coronary events
40. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial
41. The role of the cardiovascular specialist in the prevention of cardiovascular diseases - Executive summary
42. Persistence of use of lipid-lowering medications: A cross-national study
43. Familial hypoalphalipoproteinemia in premature coronary artery disease